Current stock page

Financial Data

SNDX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

SNDXSyndax Pharmaceuticals, Inc.

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 2/10
$9.45−$0.09 (−0.94%)

Latest quote

  • Momentum
    14
  • Value
    64
  • Quality
    66
  • Risk resilience
    37
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$83.3M$72.79M$64.86M$68.48M$45.87M$37.96M$20.04M$7.68M
Gross Profit$69.3M$69.58M$62.23M$70.05M$43.77M$36.68M$19.16M$7.68M
Operating Income-$41.9M-$40M-$34.2M-$62.55M-$57.43M-$69.35M-$83.76M-$96.37M
Net Income-$49.43M-$49.36M-$42.67M-$68.01M-$60.72M-$71.85M-$84.85M-$94.17M
EPS-$0.55-$0.55-$0.49-$0.78-$0.7-$0.83-$0.99-$1.1
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$27.25M-$30.27M-$50.35M-$69.49M-$70.54M-$87.8M-$95.16M-$57.39M
Capital Expenditure$0-$40K$0-$56K-$131K$0$0$0
Free Cash Flow-$27.25M-$30.31M-$50.35M-$69.54M-$70.67M-$87.8M-$95.16M-$57.39M
Net Cash Provided By Operating Activities-$27.25M-$30.27M-$50.35M-$69.49M-$70.54M-$87.8M-$95.16M-$57.39M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$692.67M$703.65M$472.67M$529.71M$551.79M$596.15M$640.71M$724.82M
Total Debt$589.42M$589.38M$345.36M$346.48M$345.43M$1.68M$1.84M$345.74M
Cash And Cash Equivalents$135.94M$336.48M$130.89M$134.93M$116.81M$108.64M$153.99M$154.08M
Total Liabilities$709.85M$688.55M$431.05M$465.08M$436.36M$438.73M$425.65M$436.69M
Total Stockholders Equity-$17.18M$15.1M$41.62M$64.63M$115.43M$157.42M$215.06M$288.12M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio—112.4544.627.710.335.695.44.61
P/S ratio2.93———————
Debt To Equity—39.038.35.362.990.010.011.2
Free Cash Flow Yield-21.09%-13.01%-14.99%-18.05%-26.09%-33.77%-24.66%-20.70%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio—112.4544.627.710.335.695.44.61
P/S ratio2.93———————
Return On Equity—-14.62%-5.84%-4.42%-269.93%-212.79%-154.01%-110.63%
Debt To Equity—39.038.35.362.990.010.011.2

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-3.99x
Pb-49.39x
Revenue Growth Yoy81.59%
EPS Growth Yoy21.43%
Gross Margin93.69%
Operating Margin-61.72%
ROE-804.38%
ROIC-31.22%
Debt To Equity-34.31
FCF Yield-20.86%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$9.45
Volume3.18M
RSI (14)26.22
MACD-1.75
MACD signal-1.59
MACD histogram-0.16
ADX (14)47.75
SMA (50)$15.27
SMA (200)$19.72
ATR (14)$0.92
Historical volatility (annualized)113.26%
Volume (20-day average)4.01M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score37/100
Beta0.77
Annual volatility57.16%
Max Drawdown-62.74%
Sharpe Ratio-0.76
VaR (95%, 1-day)-4.55%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

SNDX Financial Data FAQ

What is Syndax Pharmaceuticals, Inc.'s revenue?

Syndax Pharmaceuticals, Inc.'s revenue is one of the core financial data points for SNDX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Syndax Pharmaceuticals, Inc.'s revenue growing?

Revenue growth shows whether Syndax Pharmaceuticals, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is SNDX's EPS?

SNDX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Syndax Pharmaceuticals, Inc.'s net income?

Syndax Pharmaceuticals, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Syndax Pharmaceuticals, Inc. generate?

Free cash flow shows how much cash Syndax Pharmaceuticals, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Syndax Pharmaceuticals, Inc. have?

Cash and debt help frame SNDX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.